| Biomarker ID | 531 |
| PMID | 20473923 |
| Year | 2010 |
| Biomarker | KLK15 (kallikrein-related peptidase) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Intrinsic Prothrombin Activation Pathway,MSP-RON Signaling, PPAR Alpha Pathway,Blood Coagulation Cascade |
| Experiment | Prostate Cancer Vs Normal Adjacent |
| Type of Biomarker | Diagnostic |
| Cohort | For mRNA analysis, 25 patients with radical prostatectomies were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.045 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | KLK15 levels in tumour tissue according to median suggested an asso- ciation of higher KLK15 expression with shorter progression free survival, the latter defined by PSA relapse (data in supplementry material) |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | KLK15 |